Vidofludimus Calcium Demonstrates Therapeutic Potential in Latest Phase 2 CALLIPER Trial Data of Progressive Multiple Sclerosis

Published Date: 02 May 2025

Overall, Vidofludimus calcium demonstrated a 20% reduction in confirmed disability worsening events and modest benefits on brain volume change in patients with progressive multiple sclerosis.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

The Boom in ADHD Coaching Has Few Rules

2.

Cancer patients with HIV have demonstrated safety with immune checkpoint inhibitors.

3.

The FDA approves Enhertu for HER2-positive cancers, regardless of tumor type.

4.

Medicaid expansion tied to smaller declines in early-stage cancer detection

5.

Specialist Referrals Are Critical for Functional High-Risk Multiple Myeloma


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot